AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31518644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Vorinostat
Number of subjects: 16
Study 28566524 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet (MedDiet)
Number of subjects: 166
Study 28566524 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual Diet (HabDiet)
Number of subjects: 166
Study 25862517 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with capecitabine and bevacizumab
Number of subjects: 558
Study 25862517 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 558
Study 23123046 — intervention group
Group type: EXPERIMENTAL
Intervention: solution-focused therapy
Number of subjects: 326
Study 23123046 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term psychodynamic psychotherapy
Number of subjects: 326
Study 23123046 — intervention group
Group type: EXPERIMENTAL
Intervention: long-term psychodynamic psychotherapy
Number of subjects: 326
Study 23123046 — intervention group
Group type: COMPARATOR
Intervention: short-term or long-term therapy
Number of subjects: 326
Study 21372697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive-behavior therapy (CBT) for 6 weeks
Number of subjects: 71
Study 21372697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study 19921983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 5 mg/day for 5 weeks
Number of subjects: 75
Study 19921983 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens 160 mg/day for 5 weeks
Number of subjects: 75
Study 19921983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study 16432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 40
Study 16432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 40
Study 16432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 40
Study 16432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 32 mg
Number of subjects: 40
Study 16432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 64 mg
Number of subjects: 40
Study 16432265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12973135 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intradiscal radiofrequency thermocoagulation for 120 seconds at 80C
Number of subjects: 39
Study 12973135 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intradiscal radiofrequency thermocoagulation for 360 seconds at 80C
Number of subjects: 39
Study 11732512 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic feedback control system
Number of subjects: 22
Study 11732512 — intervention group
Group type: COMPARATOR
Intervention: Human control (manual method)
Number of subjects: 22
Study 9039547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0
Study 9039547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 9039547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against MAC
Number of subjects: 0
Study 1302472 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alternating with radiotherapy (4 cycles of intravenous cisplatin 20 mg/m²/day for 5 days and fluorouracil 200 mg/m²/day for 5 days, alternating with radiotherapy in three 2-week courses of 20 Gy per course, 2 Gy per day, 5 days per week)
Number of subjects: 157
Study 1302472 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (up to 70 Gy; 2 Gy per day, 5 days per week)
Number of subjects: 157
Study 1302472 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alternating with radiotherapy
Number of subjects: 157
Study 1302472 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 157
Study 4001761 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle meatal antrostomy
Number of subjects: 38
Study 4001761 — intervention group
Group type: COMPARATOR
Intervention: Inferior meatal antrostomy
Number of subjects: 38
Study 29320597 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 70 sunscreen applied at 2 mg/cm2
Number of subjects: 24
Study 29320597 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 70 sunscreen applied at 1 mg/cm2
Number of subjects: 24
Study 29320597 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen applied at 2 mg/cm2
Number of subjects: 24
Study 29320597 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen applied at 1 mg/cm2
Number of subjects: 24
Study 29320597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dose study groups (SPF 15 and 70)
Number of subjects: 24
Study 27497456 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered web-based/digital Breaking Bad News communication training module
Number of subjects: 0
Study 27497456 — intervention group
Group type: EXPERIMENTAL
Intervention: Other similarly designed modules (Living Through Treatment, Transitions, Spirituality, Family)
Number of subjects: 0
Study 23954085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) testing offered at 4-year intervals
Number of subjects: 34833
Study 23954085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) testing after correction for nonattendance and contamination
Number of subjects: 34833
Study 23954085 — intervention group
Group type: COMPARATOR
Intervention: Screening (PSA testing)
Number of subjects: 34833
Study 23008825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x8 Gy preoperative intracavitary HDR BT followed by radical surgery
Number of subjects: 100
Study 23008825 — intervention group
Group type: COMPARATOR
Intervention: No preoperative treatment before planned radical Wertheim hysterectomy
Number of subjects: 100
Study 20353496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (proton pump inhibitors or H(2)-receptor antagonists)
Number of subjects: 9989
Study 20353496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9989
Study 20353496 — intervention group
Group type: COMPARATOR
Intervention: PPI therapy
Number of subjects: 9989
Study 18671147 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate (90 micrograms/puff)
Number of subjects: 20
Study 18671147 — intervention group
Group type: COMPARATOR
Intervention: Albuterol/Ipratropium bromide (90 micrograms/puff/18 micrograms/puff)
Number of subjects: 20
Study 15832349 — intervention group
Group type: EXPERIMENTAL
Intervention: Claw foot (CFS)
Number of subjects: 72
Study 15832349 — intervention group
Group type: COMPARATOR
Intervention: Normal foot (NFS)
Number of subjects: 72
Study 12410709 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly NB-UVB phototherapy (Monday and Friday)
Number of subjects: 113
Study 12410709 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly NB-UVB phototherapy (Monday, Wednesday and Friday)
Number of subjects: 113
Study 9864001 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg twice daily by Turbohaler)
Number of subjects: 10
Study 9864001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7618771 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lidocaine
Number of subjects: 45
Study 7618771 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 45
Study 7618771 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm lidocaine
Number of subjects: 45
Study 7618771 — intervention group
Group type: COMPARATOR
Intervention: Need for additional anesthesia
Number of subjects: 45
Study 7618771 — intervention group
Group type: COMPARATOR
Intervention: Pain on suturing
Number of subjects: 45
Study 2224060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg/bw per os daily)
Number of subjects: 101
Study 2224060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 12262389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Depo-Provera and Depo-Testosterone
Number of subjects: 0
Study 12262389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of drug administration
Number of subjects: 0
Study 12262389 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug administration
Number of subjects: 0
Study 12262389 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance doses of the drug
Number of subjects: 0
Study 31640791 — intervention group
Group type: EXPERIMENTAL
Intervention: VFC (vibrotactile feedback)
Number of subjects: 141
Study 31640791 — intervention group
Group type: EXPERIMENTAL
Intervention: VFC+ (vibrotactile feedback + web portal)
Number of subjects: 141
Study 31640791 — intervention group
Group type: EXPERIMENTAL
Intervention: VFC and VFC+
Number of subjects: 141
Study 31640791 — intervention group
Group type: COMPARATOR
Intervention: NFC (no feedback)
Number of subjects: 141
Study 29325884 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain (unilateral and bilateral) in R‐LBP patients
Number of subjects: 53
Study 29325884 — intervention group
Group type: COMPARATOR
Intervention: Experimental pain (unilateral and bilateral) in healthy controls
Number of subjects: 53
Study 29325884 — intervention group
Group type: COMPARATOR
Intervention: Experimental pain (bilateral)
Number of subjects: 53
Study 26862813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 530
Study 26862813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 26213503 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials targeted to health literacy levels and learning styles
Number of subjects: 160
Study 26213503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 23954165 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 224
Study 23954165 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 224
Study 20807462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% (w/v) Longjing green tea
Number of subjects: 18
Study 20807462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% (w/v) screw-shaped green tea
Number of subjects: 18
Study 20807462 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 18
Study 18215746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-Energy Manual Therapy (OEMT) for six sessions
Number of subjects: 23
Study 18215746 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (oscillating energy directed to an area above or below the tender points)
Number of subjects: 23
Study 16774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0
Study 16774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma
Number of subjects: 0
Study 16774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 0
Study 16774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 0
Study 16774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor
Number of subjects: 0
Study 14728888 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPT) intravenously (30 mg/kg) for 3 days followed by oral prednisone
Number of subjects: 30
Study 14728888 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPT)
Number of subjects: 30
Study 10859047 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with fibrin-stabilising factor XIII
Number of subjects: 0
Study 10859047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9174312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (1 mg)
Number of subjects: 23
Study 9174312 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular saline
Number of subjects: 23
Study 9174312 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 23
Study 9174312 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 23
Study 8457047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (temperature < 35 degrees C)
Number of subjects: 100
Study 8457047 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (temperature >= 35 degrees C)
Number of subjects: 100
Study 8457047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group
Number of subjects: 100
Study 8457047 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group
Number of subjects: 100
Study 3920301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG), 20 mg, four times a day for 6 weeks
Number of subjects: 22
Study 3920301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3920301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 22
Study 30243061 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐shot paravertebral block with 0.2% ropivacaine with 1:200000 adrenaline
Number of subjects: 50
Study 28833067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty hour policy
Number of subjects: 0
Study 28833067 — intervention group
Group type: COMPARATOR
Intervention: Standard duty hour policy
Number of subjects: 0
Study 26021213 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 90
Study 25735811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot‐BITs treatment (Hometreatment brings inpatient‐treatment outside), 12 weeks of intensive support after early discharge.
Number of subjects: 100
Study 25735811 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard inpatient treatment).
Number of subjects: 100
Study 22228239 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP of 20 cmH2O (group C)
Number of subjects: 240
Study 22228239 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP of 25 cmH2O (group D)
Number of subjects: 240
Study 22228239 — intervention group
Group type: COMPARATOR
Intervention: PAP of 0 cmH2O (group A)
Number of subjects: 240
Study 22228239 — intervention group
Group type: COMPARATOR
Intervention: PAP of 15 cmH2O (group B)
Number of subjects: 240
Study 20381672 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise in Fontan patients
Number of subjects: 29
Study 20381672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction in Fontan patients
Number of subjects: 29
Study 20381672 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise with indwelling catheters in Fontan patients
Number of subjects: 29
Study 18332759 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading with platelet rich plasma (PRP) and 50% autogenous bone combined with substitute graft materials
Number of subjects: 41
Study 15990457 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-helical CRH
Number of subjects: 7
Study 15526508 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol, 12.5 mg/day for six days
Number of subjects: 50
Study 15526508 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six days
Number of subjects: 50
Study 11220558 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing mode
Number of subjects: 78
Study 11220558 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing mode
Number of subjects: 78
Study 7782727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 50
Study 7782727 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 50
Study 3293257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine‐A (CyA) 5 mg/kg/day for 6 months
Number of subjects: 20
Study 3293257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3293257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine‐A (CyA) 5 mg/kg/day for an additional 6 months (open trial)
Number of subjects: 20
Study 3293257 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of CyA
Number of subjects: 20
Study 31769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal influenza immunization
Number of subjects: 3693
Study 31769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrheal illness
Number of subjects: 3693
Study 31769386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3693
Study 30575648 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 0
Study 30575648 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 28412960 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser transurethral vaporesection of the prostate (ThuVARP)
Number of subjects: 410
Study 28412960 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 410
Study 25170104 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron rgp120 with MF59
Number of subjects: 118
Study 25170104 — intervention group
Group type: EXPERIMENTAL
Intervention: VaxGen rgp120 with aluminum hydroxide (alum)
Number of subjects: 118
Study 25170104 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV-1/AIDSVAX B/B with alum
Number of subjects: 118
Study 25170104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PACTG 230)
Number of subjects: 118
Study 25170104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PACTG 326)
Number of subjects: 118
Study 22642697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 750 mg dose telaprevir with 400 mg ketoconazole
Number of subjects: 3
Study 22642697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of telaprevir with 400 mg ketoconazole
Number of subjects: 3
Study 22642697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 750 mg dose telaprevir with 600 mg rifampicin
Number of subjects: 3
Study 22642697 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg every 8 h telaprevir with 600 mg efavirenz
Number of subjects: 3
Study 21807759 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DAC) high dose with interferon beta (IFNβ)
Number of subjects: 64
Study 21807759 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (DAC) low dose with interferon beta (IFNβ)
Number of subjects: 64
Study 21807759 — intervention group
Group type: COMPARATOR
Intervention: Placebo with interferon beta (IFNβ)
Number of subjects: 64
Study 21807759 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DAC dose
Number of subjects: 64
Study 21807759 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher expression of intermediate-affinity IL-2 receptor subunit (CD122) on CD56(bright) NK cells
Number of subjects: 64
Study 18485139 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralising toothpaste (Enamelon)
Number of subjects: 57
Study 18485139 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice
Number of subjects: 57
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM cement with acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM cement without acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA without acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI with acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI without acid etching
Number of subjects: 90
Study 22269237 — intervention group
Group type: COMPARATOR
Intervention: MTA and CEM
Number of subjects: 90
Study 22269237 — intervention group
Group type: EXPERIMENTAL
Intervention: All materials (MTA, CEM, RMGI)
Number of subjects: 90
Study 16194003 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR-administered Brief Symptom Inventory (BSI)
Number of subjects: 0
Study 16194003 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil survey administration
Number of subjects: 0
Study 12021631 — intervention group
Group type: EXPERIMENTAL
Intervention: AcMPAG in stable phase (3-12 months)
Number of subjects: 38
Study 12021631 — intervention group
Group type: COMPARATOR
Intervention: AcMPAG in initial phase (1-3 weeks)
Number of subjects: 38
Study 12021631 — intervention group
Group type: EXPERIMENTAL
Intervention: AcMPAG-AUC(12h)
Number of subjects: 38
Study 12021631 — intervention group
Group type: EXPERIMENTAL
Intervention: AcMPAG concentrations
Number of subjects: 38
Study 12021631 — intervention group
Group type: EXPERIMENTAL
Intervention: AcMPAG-Alb adducts
Number of subjects: 38
Study 9739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift (0000-1200 h) for Crew 2 (n = 7) studied in March
Number of subjects: 18
Study 9739990 — intervention group
Group type: COMPARATOR
Intervention: Night shift (0000-1200 h) for Crew 1 (n = 11) studied in November
Number of subjects: 18
Study 7802313 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg)
Number of subjects: 33
Study 7802313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nubain (0.3 mg/kg)
Number of subjects: 33
Study 7802313 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 33
Study 2454140 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (1.0 to 3.0 ng/kg/min)
Number of subjects: 12
Study 2454140 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 12617436 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (Cohort 1) - GPs identified patients with DU and prescribed HPET according to defined criteria.
Number of subjects: 1422
Study 12617436 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (Cohort 2) - GPs prescribed HPET later.
Number of subjects: 1422
Study 31220957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20% infusion on the day of embryo transfer and a second dose on the day of pregnancy test
Number of subjects: 142
Study 31220957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intralipid therapy)
Number of subjects: 142
Study 29736496 — intervention group
Group type: EXPERIMENTAL
Intervention: Paneer
Number of subjects: 60
Study 29736496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 60